Heinrich Lannert

Title: Heinrich Lannert: Innovator in Prostate Cancer Treatment

Introduction

Heinrich Lannert is a notable inventor based in Schwetzingen, Germany. He has made significant contributions to the field of cancer treatment, particularly focusing on prostate cancer. His innovative work has led to the development of a patent that addresses a critical medical need.

Latest Patents

Lannert holds a patent for an "Anti-alpha-V integrin antibody for the treatment of prostate cancer." This invention is directed towards the treatment of prostate cancer using antibodies. Specifically, it involves the administration of an anti-alpha-v integrin antibody to patients suffering from prostate cancer, especially those with castration-resistant prostate cancer (CRPC), which may include lymph node and bone tissue metastases (mCRPC). The therapy utilizes the anti-angiogenic antibody DI17E6 and its structural mutants.

Career Highlights

Heinrich Lannert is associated with Merck Patent GmbH, where he has been instrumental in advancing cancer treatment methodologies. His work has not only contributed to scientific knowledge but also has the potential to improve patient outcomes in prostate cancer therapy.

Collaborations

Lannert has collaborated with notable colleagues such as Benoît Destenaves and Juergen Reindl. These partnerships have fostered a collaborative environment that enhances innovation and research in the field of oncology.

Conclusion

Heinrich Lannert's contributions to the treatment of prostate cancer through his patented invention highlight his role as an important figure in medical innovation. His work continues to pave the way for advancements in cancer therapies.